SecBot SecBot
SC 13G/A ·Filed Nov 10, 2026

LGND

LIGAND PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed6d 10h ago SEC0000914208-26-000430
Passive stake amendment
Actionable Insight • Neutral

Invesco's passive stake increase is routine and immaterial. Monitor for any future conversion to a Schedule 13D, which would signal activist intent, but no such signal is present here.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$316.83
T+0 close · Nov 10, 2026 · via day close
Latest settled
−0.18%
T+1 · $316.27
Vs SPY
+0.18%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $316.83entry
  2. T+1 · 5d ago −0.18%α +0.18% · $316.27
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Invesco Ltd. filed an amended Schedule 13G disclosing a 7.6% passive stake in Ligand Pharmaceuticals as of September 30, 2026, up from 1,497,232 shares in the prior filing to 1,520,911 shares. The increase is modest and consistent with passive portfolio rebalancing, with no indication of activist intent.

Key Financial Metrics

Stake
7.6%
Investor
Invesco Ltd.
Investor Type
hedge fund

Key Facts

  • Invesco Ltd. reported beneficial ownership of 1,520,911 shares of Ligand Pharmaceuticals common stock as of September 30, 2026
  • The stake represents 7.6% of shares outstanding
  • This is an amendment to a prior Schedule 13G filed August 13, 2026, which reported 1,497,232 shares
  • The increase of approximately 23,679 shares is small and consistent with passive investment management
  • Invesco certifies the shares were acquired and held in the ordinary course of business, not for changing or influencing control

Financial Impact

Invesco holds 1,520,911 shares valued at approximately $380M based on the $6.1B market cap and 7.6% stake

ownership_percentage

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0000914208-26-000430
Document: 0000914208-26-000430-index.html0000914208-26-000430
Document: 0000914208-26-000430.txt0000914208-26-000430

Track record

29 reports on LGND

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
  6. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Viewing Entry $316.83 Now $301.71 −4.77% settles Feb 9
  7. Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
  8. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
  9. Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
  10. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026